A1CF | APOBEC1 complementation factor | | | | | | Tissue enhanced |
AADAT | Aminoadipate aminotransferase | Enzymes Mitochondrial proteins
| | | | | Tissue enhanced |
ABAT | 4-aminobutyrate aminotransferase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Tissue enhanced |
ABCA3 | ATP-binding cassette, sub-family A (ABC1), member 3 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCA9 | ATP-binding cassette, sub-family A (ABC1), member 9 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCB1 | ATP-binding cassette, sub-family B (MDR/TAP), member 1 | Cancer-related genes CD markers Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCC11 | ATP-binding cassette, sub-family C (CFTR/MRP), member 11 | Predicted membrane proteins
| | | | | Tissue enhanced |
ABCC6 | ATP-binding cassette, sub-family C (CFTR/MRP), member 6 | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCD2 | ATP-binding cassette, sub-family D (ALD), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
AC131097.4 | Protein LOC285095 | | | | | | Tissue enhanced |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACOX2 | Acyl-CoA oxidase 2, branched chain | Enzymes
| | | | | Tissue enhanced |
ACY3 | Aspartoacylase (aminocyclase) 3 | Enzymes
| | | | | Tissue enhanced |
ADAM8 | ADAM metallopeptidase domain 8 | CD markers Enzymes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif, 1 | Cancer-related genes Enzymes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS13 | ADAM metallopeptidase with thrombospondin type 1 motif, 13 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTSL4 | ADAMTS-like 4 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
ADCY2 | Adenylate cyclase 2 (brain) | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
ADIRF | Adipogenesis regulatory factor | Plasma proteins
| | | | | Tissue enhanced |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AFAP1L2 | Actin filament associated protein 1-like 2 | | | | | | Tissue enhanced |
AGAP2 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | | | | | | Tissue enhanced |
AGMAT | Agmatine ureohydrolase (agmatinase) | Enzymes Mitochondrial proteins
| | | | | Tissue enhanced |
AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
AGR3 | Anterior gradient 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
AIF1L | Allograft inflammatory factor 1-like | | | | | | Tissue enhanced |
AIM1L | Absent in melanoma 1-like | | | | | | Tissue enhanced |
AK4 | Adenylate kinase 4 | Enzymes Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AK7 | Adenylate kinase 7 | Enzymes
| | | | | Tissue enhanced |
AKAP5 | A kinase (PRKA) anchor protein 5 | Plasma proteins
| | | | | Tissue enhanced |
AKAP6 | A kinase (PRKA) anchor protein 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
AKNAD1 | AKNA domain containing 1 | | | | | | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
ALDH1A3 | Aldehyde dehydrogenase 1 family, member A3 | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
ALDH1L1 | Aldehyde dehydrogenase 1 family, member L1 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
ALDH1L2 | Aldehyde dehydrogenase 1 family, member L2 | Enzymes
| | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
ALOX5 | Arachidonate 5-lipoxygenase | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
ALPK2 | Alpha-kinase 2 | Cancer-related genes Enzymes
| | | | | Tissue enhanced |
ALPL | Alkaline phosphatase, liver/bone/kidney | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ALX1 | ALX homeobox 1 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
ANK1 | Ankyrin 1, erythrocytic | Cytoskeleton related proteins Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ANKEF1 | Ankyrin repeat and EF-hand domain containing 1 | | | | | | Tissue enhanced |
ANKRD45 | Ankyrin repeat domain 45 | | | | | | Tissue enhanced |
ANKRD65 | Ankyrin repeat domain 65 | | | | | | Tissue enhanced |
ANLN | Anillin, actin binding protein | | | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |